369 related articles for article (PubMed ID: 34169568)
21. Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA.
Bello M; Martínez-Muñoz A; Balbuena-Rebolledo I
J Mol Model; 2020 Nov; 26(12):340. PubMed ID: 33184722
[TBL] [Abstract][Full Text] [Related]
22. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
[TBL] [Abstract][Full Text] [Related]
23. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
[TBL] [Abstract][Full Text] [Related]
24.
Iype E; Pillai U J; Kumar I; Gaastra-Nedea SV; Subramanian R; Saha RN; Dutta M
J Biomol Struct Dyn; 2022; 40(23):12800-12811. PubMed ID: 34550861
[TBL] [Abstract][Full Text] [Related]
25. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
Refaey RH; El-Ashrey MK; Nissan YM
Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
[TBL] [Abstract][Full Text] [Related]
26. Deciphering the binding mechanism of inhibitors of the SARS-CoV-2 main protease through multiple replica accelerated molecular dynamics simulations and free energy landscapes.
Li M; Liu X; Zhang S; Liang S; Zhang Q; Chen J
Phys Chem Chem Phys; 2022 Sep; 24(36):22129-22143. PubMed ID: 36082845
[TBL] [Abstract][Full Text] [Related]
27. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
28. QSAR Modeling of SARS-CoV M
Alves VM; Bobrowski T; Melo-Filho CC; Korn D; Auerbach S; Schmitt C; Muratov EN; Tropsha A
Mol Inform; 2021 Jan; 40(1):e2000113. PubMed ID: 33405340
[TBL] [Abstract][Full Text] [Related]
29. Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.
Choudhury C
J Biomol Struct Dyn; 2021 Jul; 39(10):3733-3746. PubMed ID: 32452282
[TBL] [Abstract][Full Text] [Related]
30. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
31. Repurposing drug molecule against SARS-Cov-2 (COVID-19) through molecular docking and dynamics: a quick approach to pick FDA-approved drugs.
Farhat N; Khan AU
J Mol Model; 2021 Oct; 27(11):312. PubMed ID: 34601658
[TBL] [Abstract][Full Text] [Related]
32. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
Kumar R; Kumar V; Lee KW
Comput Biol Med; 2021 Mar; 130():104186. PubMed ID: 33360831
[TBL] [Abstract][Full Text] [Related]
33. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
34. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
35. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
Rakib A; Nain Z; Sami SA; Mahmud S; Islam A; Ahmed S; Siddiqui ABF; Babu SMOF; Hossain P; Shahriar A; Nainu F; Emran TB; Simal-Gandara J
Brief Bioinform; 2021 Mar; 22(2):1476-1498. PubMed ID: 33623995
[TBL] [Abstract][Full Text] [Related]
36. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
[TBL] [Abstract][Full Text] [Related]
37. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
Günther S; Reinke PYA; Fernández-García Y; Lieske J; Lane TJ; Ginn HM; Koua FHM; Ehrt C; Ewert W; Oberthuer D; Yefanov O; Meier S; Lorenzen K; Krichel B; Kopicki JD; Gelisio L; Brehm W; Dunkel I; Seychell B; Gieseler H; Norton-Baker B; Escudero-Pérez B; Domaracky M; Saouane S; Tolstikova A; White TA; Hänle A; Groessler M; Fleckenstein H; Trost F; Galchenkova M; Gevorkov Y; Li C; Awel S; Peck A; Barthelmess M; Schlünzen F; Lourdu Xavier P; Werner N; Andaleeb H; Ullah N; Falke S; Srinivasan V; França BA; Schwinzer M; Brognaro H; Rogers C; Melo D; Zaitseva-Doyle JJ; Knoska J; Peña-Murillo GE; Mashhour AR; Hennicke V; Fischer P; Hakanpää J; Meyer J; Gribbon P; Ellinger B; Kuzikov M; Wolf M; Beccari AR; Bourenkov G; von Stetten D; Pompidor G; Bento I; Panneerselvam S; Karpics I; Schneider TR; Garcia-Alai MM; Niebling S; Günther C; Schmidt C; Schubert R; Han H; Boger J; Monteiro DCF; Zhang L; Sun X; Pletzer-Zelgert J; Wollenhaupt J; Feiler CG; Weiss MS; Schulz EC; Mehrabi P; Karničar K; Usenik A; Loboda J; Tidow H; Chari A; Hilgenfeld R; Uetrecht C; Cox R; Zaliani A; Beck T; Rarey M; Günther S; Turk D; Hinrichs W; Chapman HN; Pearson AR; Betzel C; Meents A
Science; 2021 May; 372(6542):642-646. PubMed ID: 33811162
[TBL] [Abstract][Full Text] [Related]
38. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
[TBL] [Abstract][Full Text] [Related]
39. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
40. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
